secwatch.observer — SEC 8-K summary
======================================

Issuer:     Turn Therapeutics Inc. (TTRX)
CIK:        0002023016
Form:       8-K
Filed at:   2026-08-12T20:40:26+00:00
Accession:  0001213900-26-088411
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Turn Therapeutics Q2 net loss $5.85M; GX-03 Phase 2 interim data positive, expands study
--------------------------------------------------------------------------------

- Net loss $5.85M (-$0.20/share) vs $1.24M (-$0.05) in Q2 2025; cash $10.3M, runway into Q3 2027.
- GX-03 Phase 2 interim: 61.5% vs 8.3% clear/almost clear at Week 4; EASI-75 69.2% vs 25.0% at Week 4.
- Expanded Stage 2 to 120-135 patients including lower EASI; no serious adverse events; enrollment on track for Q4 2026.
- Appointed former FDA Commissioner Stephen Hahn as Executive Clinical and Regulatory Lead on May 18, 2026.
- Plans Phase 2a in hidradenitis suppurativa (~60 patients) targeting first dosing Q2 2027; first peer-reviewed publication May 27, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026088411/0001213900-26-088411-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026088411/ea0301772-8k_turn.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-088411

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer